# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Deane Dray maintains Xylem (NYSE:XYL) with a Outperform and raises the price target from $157 to $162.
Oppenheimer analyst Bryan Blair maintains Xylem (NYSE:XYL) with a Outperform and raises the price target from $142 to $147.
Mizuho analyst Brett Linzey maintains Xylem (NYSE:XYL) with a Neutral and raises the price target from $110 to $135.
Baird analyst Michael Halloran maintains Xylem (NYSE:XYL) with a Outperform and raises the price target from $151 to $155.
Outlook Xylem now expects full-year 2024 revenue of approximately $8.5 billion, up approximately 15 to 16 percent on a reporte...
Xylem (NYSE:XYL) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.84 by 7.14 perc...